论文部分内容阅读
目的观察布地奈德/福莫特罗粉吸入剂治疗慢性阻塞性肺疾病急性加重期(AECOPD)的效果。方法 98例AECOPD住院患者,随机分为两组,对照组49例给予常规治疗,治疗组49例给予常规治疗的同时,吸入布地奈德/福莫特罗粉吸入剂,每日2次。对比治疗后患者第一秒用力呼气容积(FEV1)占预计值百分比(FEV1%)、第一秒用力呼气容积与用力肺活量比值(FEV1/FVC)及圣乔治呼吸问卷(SGRQ)分值的变化。结果 FEV1、FEV1%、FEV1/FVC与呼吸问卷分值比较,治疗组治疗后比较治疗前明显升高,差异有统计学意义(P<0.05);对照组治疗后比较治疗前亦均有明显升高(P<0.05),但对照组的改善情况不如治疗组(P<0.05)。结论布地奈德/福莫特罗粉吸入疗法对AECOPD疗效肯定,可改善肺功能并提高生活质量,可作为治疗AECOPD的有效方案。
Objective To observe the effect of budesonide / formoterol powder inhaler on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 98 hospitalized patients with AECOPD were randomly divided into two groups. The control group received routine therapy. In the treatment group, 49 patients received conventional inhalation of budesonide and formoterol inhalation twice daily. The FEV1, FEV1 / FVC and SGRQ were compared between the first and second forced expiratory volume (FEV1%), the first second forced expiratory volume (FEV1 / FVC) and the St. George’s Respiratory Questionnaire Variety. Results FEV1, FEV1% and FEV1 / FVC were significantly higher than those of the respiratory questionnaire before treatment in the treatment group after treatment, the difference was statistically significant (P <0.05); the control group before treatment also significantly increased (P <0.05), but the improvement of the control group was not as good as the treatment group (P <0.05). Conclusions Budesonide / formoterol powder inhalation therapy has a definite curative effect on AECOPD, which can improve pulmonary function and improve quality of life. It can be used as an effective treatment for AECOPD.